Femara is composed of Letrozole as the active component. It is manufactured by one of the top pharmaceutical companies, Novartis Pharmaceuticals Corporation. This medicine is indicated for the treatment of certain types of breast cancer like hormone-receptor-positive breast cancer in women after menopause. It is available in a conventional tablet form in a dosage of 2.5 mg.
Manufacturer: Novartis Pharmaceuticals Corporation
Active Ingredient: This medication is composed of Letrozole, which is a nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. This drug aromatase inhibitor acts by inhibiting aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. It is a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and traced in many tissues with those of the premenopausal ovary, liver, and breast. This drug catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol.
Indications: This mentioned drug is indicated to treat certain types of breast cancer like hormone-receptor-positive breast cancer in women after menopause. Femara helps to prevent cancer from returning. Breast cancers are formed to grow faster by a natural hormone called estrogen. It reduces the amount of estrogen the body produces and slower or reverse the growth of breast cancers.
Action Mechanism: This medicine is composed of active component Letrozole. Femara inhibits the aromatase so as to suppress estrogen production. This drug blocks estrogen receptors. The pituitary gland makes more of the hormones needed to stimulate the ovaries.
Dosages: This drug is available for oral consumption in a dosage as mentioned below:
- 2.5 mg: Take this medication by mouth, usually once daily with or without food or as directed by your doctor.
This medication can be absorbed through the skin and lungs, pregnant women should not handle this drug or breathe the dust from the tablets.